257 related articles for article (PubMed ID: 10690558)
1. Overexpression of Bax enhances antitumor activity of chemotherapeutic agents in human head and neck squamous cell carcinoma.
Guo B; Cao S; Tóth K; Azrak RG; Rustum YM
Clin Cancer Res; 2000 Feb; 6(2):718-24. PubMed ID: 10690558
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
Cao S; McGuire JJ; Rustum YM
Clin Cancer Res; 1999 Jul; 5(7):1925-34. PubMed ID: 10430100
[TBL] [Abstract][Full Text] [Related]
3. Dimerization of mitochondrial Bax is associated with increased drug response in Bax-transfected A253 cells.
Guo B; Yin MB; Tóth K; Cao S; Azrak RG; Rustum YM
Oncol Res; 1999; 11(2):91-9. PubMed ID: 10489165
[TBL] [Abstract][Full Text] [Related]
4. The Chk1-Cdc25C regulation is involved in sensitizing A253 cells to a novel topoisomerase I inhibitor BNP1350 by bax gene transfer.
Yin M; Hapke G; Guo B; Azrak RG; Frank C; Rustum YM
Oncogene; 2001 Aug; 20(38):5249-57. PubMed ID: 11536038
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts.
Azrak RG; Cao S; Slocum HK; Tóth K; Durrani FA; Yin MB; Pendyala L; Zhang W; McLeod HL; Rustum YM
Clin Cancer Res; 2004 Feb; 10(3):1121-9. PubMed ID: 14871992
[TBL] [Abstract][Full Text] [Related]
6. Synergistic antitumor activity of capecitabine in combination with irinotecan.
Cao S; Durrani FA; Rustum YM
Clin Colorectal Cancer; 2005 Jan; 4(5):336-43. PubMed ID: 15663838
[TBL] [Abstract][Full Text] [Related]
7. Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy.
Bhattacharya A; Tóth K; Mazurchuk R; Spernyak JA; Slocum HK; Pendyala L; Azrak R; Cao S; Durrani FA; Rustum YM
Clin Cancer Res; 2004 Dec; 10(23):8005-17. PubMed ID: 15585636
[TBL] [Abstract][Full Text] [Related]
8. Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts.
Cao S; Durrani FA; Rustum YM
Clin Cancer Res; 2004 Apr; 10(7):2561-9. PubMed ID: 15073137
[TBL] [Abstract][Full Text] [Related]
9. Raltitrexed induces mitochondrial‑mediated apoptosis in SGC7901 human gastric cancer cells.
Xue S; Chen YX; Qin SK; Yang AZ; Wang L; Xu HJ; Geng HY
Mol Med Rep; 2014 Oct; 10(4):1927-34. PubMed ID: 25109431
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts.
Bhattacharya A; Tóth K; Durrani FA; Cao S; Slocum HK; Chintala S; Rustum YM
Neoplasia; 2008 Aug; 10(8):857-65. PubMed ID: 18670644
[TBL] [Abstract][Full Text] [Related]
11. Phosphorylation of chk1 at serine-345 affected by topoisomerase I poison SN-38.
Hapke G; Yin MB; Wu J; Frank C; Rustum YM
Int J Oncol; 2002 Nov; 21(5):1059-66. PubMed ID: 12370755
[TBL] [Abstract][Full Text] [Related]
12. Potentiation of irinotecan sensitivity by Se-methylselenocysteine in an in vivo tumor model is associated with downregulation of cyclooxygenase-2, inducible nitric oxide synthase, and hypoxia-inducible factor 1alpha expression, resulting in reduced angiogenesis.
Yin MB; Li ZR; Tóth K; Cao S; Durrani FA; Hapke G; Bhattacharya A; Azrak RG; Frank C; Rustum YM
Oncogene; 2006 Apr; 25(17):2509-19. PubMed ID: 16518418
[TBL] [Abstract][Full Text] [Related]
13. Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors.
Azrak RG; Yu J; Pendyala L; Smith PF; Cao S; Li X; Shannon WD; Durrani FA; McLeod HL; Rustum YM
Mol Cancer Ther; 2005 May; 4(5):843-54. PubMed ID: 15897249
[TBL] [Abstract][Full Text] [Related]
14. Involvement of cyclin D1-cdk5 overexpression and MCM3 cleavage in bax-associated spontaneous apoptosis and differentiation in an A253 human head and neck carcinoma xenograft model.
Yin MB; Tóth K; Cao S; Guo B; Frank C; Slocum HK; Rustum YM
Int J Cancer; 1999 Oct; 83(3):341-8. PubMed ID: 10495426
[TBL] [Abstract][Full Text] [Related]
15. Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo.
Pollack IF; Erff M; Bom D; Burke TG; Strode JT; Curran DP
Cancer Res; 1999 Oct; 59(19):4898-905. PubMed ID: 10519402
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice.
Kawato Y; Furuta T; Aonuma M; Yasuoka M; Yokokura T; Matsumoto K
Cancer Chemother Pharmacol; 1991; 28(3):192-8. PubMed ID: 1855276
[TBL] [Abstract][Full Text] [Related]
17. Alteration of the Bcl-2/Bax status of head and neck cancer cell lines by chemotherapeutic agents.
Kawakami K; Tsukuda M; Mizuno H; Nishimura G; Ishii A; Hamajima K
Anticancer Res; 1999; 19(5B):3927-32. PubMed ID: 10628333
[TBL] [Abstract][Full Text] [Related]
18. Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.
Wang H; Wang S; Nan L; Yu D; Agrawal S; Zhang R
Int J Oncol; 2002 Apr; 20(4):745-52. PubMed ID: 11894120
[TBL] [Abstract][Full Text] [Related]
19. [Drug clinics. How I treat. II. Therapeutic approaches to metastatic colorectal cancer].
Jerusalem G; Bours V; Fillet G
Rev Med Liege; 1998 Jun; 53(6):318-21. PubMed ID: 9713208
[TBL] [Abstract][Full Text] [Related]
20. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma.
Ulrich-Pur H; Raderer M; Verena Kornek G; Schüll B; Schmid K; Haider K; Kwasny W; Depisch D; Schneeweiss B; Lang F; Scheithauer W
Br J Cancer; 2003 Apr; 88(8):1180-4. PubMed ID: 12698181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
